Induced ribotide reductive conversion defect by hydroxyurea and its relationship to megaloblastosis.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D001854:Bone Marrow Cells; D001855:Bone Marrow Diseases / Q000139:chemically induced*; D003597:Cytosine Nucleotides / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D005260:Female; D051381:Rats; D013154:Spleen / Q000378:metabolism; D013950:Thymus Gland / Q000378:metabolism; D014508:Urea / Q000009:adverse effects*
D000970:Antineoplastic Agents; D003597:Cytosine Nucleotides; D004273:DNA, Neoplasm; D014508:Urea